pantoprazole

Brand: Protonix

Prototype: omeprazole
Drug Class: proton pump inhibitor
Drug Family: GI agent
Subclass: H+/K+-ATPase inhibitor
Organ Systems: gastrointestinal

Mechanism of Action

Benzimidazole PPI; least CYP2C19-dependent of older PPIs; preferred when clopidogrel co-administration required.

H+/K+-ATPase

Indications

  • GERD
  • erosive esophagitis
  • PUD
  • Zollinger-Ellison
  • ICU stress ulcer prophylaxis (IV)

Contraindications

  • rilpivirine
  • atazanavir

Adverse Effects

Common

  • headache
  • diarrhea
  • nausea

Serious

  • hypomagnesemia
  • C. diff
  • fracture risk

Pharmacokinetics (ADME)

Absorption ~77% oral
Distribution moderate
Metabolism CYP2C19 (but less CYP2C19-dependent than omeprazole)
Excretion renal 71%
Half-life 1 hour
Onset 1-3 hours
Peak 2-4 hours
Duration 24 hours
Protein Binding 98%
Vd 0.15 L/kg

Drug Interactions

Drug / Agent Mechanism Severity
clopidogrel minimal CYP2C19 inhibition — preferred PPI with clopidogrel minor
methotrexate reduces MTX clearance — high-dose MTX toxicity risk major

Nursing Considerations

  1. Preferred PPI when clopidogrel co-administration required (least CYP2C19 inhibition)
  2. IV formulation available for ICU stress ulcer prophylaxis and when oral not possible
  3. 30-60 min before meals

Clinical Pearls

  • Preferred with clopidogrel: less CYP2C19 inhibition than omeprazole, lansoprazole, esomeprazole
  • IV pantoprazole: useful in upper GI bleeding and NPO patients

Safety Profile

Pregnancy safe
Lactation use-with-caution
Renal Adjustment Not required
Hepatic Adjustment Not required
TDM Not required

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.